Rituximab + Cytotoxic Combination
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Behcet's Syndrome
Conditions
Behcet's Syndrome
Trial Timeline
Apr 1, 2006 → Jan 1, 2008
NCT ID
NCT00664599About Rituximab + Cytotoxic Combination
Rituximab + Cytotoxic Combination is a phase 2 stage product being developed by Roche for Behcet's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00664599. Target conditions include Behcet's Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00664599 | Phase 2 | Completed |
Competing Products
2 competing products in Behcet's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abatacept | Bristol Myers Squibb | Phase 1 | 32 |
| Placebo + Gevokizumab | XOMA | Phase 3 | 69 |